Organovo Holdings Inc ONVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONVO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.00
- Day Range
- $0.99–1.03
- 52-Week Range
- $0.89–2.05
- Bid/Ask
- $0.99 / $1.25
- Market Cap
- $10.08 Mil
- Volume/Avg
- 357 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 36.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.organovo.com
Valuation
|
Metric
|
ONVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.59 |
Price/Sales | 36.43 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONVO
|
|---|---|
Quick Ratio | 3.13 |
Current Ratio | 3.67 |
Interest Coverage | — |
Quick Ratio
ONVO
Profitability
|
Metric
|
ONVO
|
|---|---|
Return on Assets (Normalized) | −110.86% |
Return on Equity (Normalized) | −138.84% |
Return on Invested Capital (Normalized) | −125.43% |
Return on Assets
ONVO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fhfdzcryx | Hghf | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xtqkpptx | Pyqmzgw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ymfcjxwv | Jzwxj | $99.5 Bil | |
MRNA
| Moderna Inc | Jtrwvpqbp | Fsmlt | $38.8 Bil | |
ARGX
| argenx SE ADR | Sdrxbyth | Tjs | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kjnsbrdvs | Mdb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vkggsclbm | Ygjmfv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zsklymqph | Zbszfs | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nfllcsbv | Lqwqx | $12.5 Bil | |
INCY
| Incyte Corp | Fgfgxzvm | Zbnyn | $11.6 Bil |